Glioblastoma Clinical Trials for New Treatments
The Ivy Center’s robust glioblastoma clinical trials program offers new treatment options to brain cancer patients.
Ivy Center’s blog states that it runs a Phase 0/1/2 clinical‑trial program for glioblastoma multiforme (GBM), developing novel therapies such as sonodynamic therapy, FGFR inhibitors, CDK4/6 and ERK inhibitors, PARP inhibitors, and an ATM kinase inhibitor. The program includes several active trials and multiple forthcoming studies aimed at improving survival for patients who normally have a five‑year survival rate of only about 6.8%. The article highlights the rapid patient‑specific approach of Phase 0 trials, the enrollment of 30–57 participants in the current trials, and the use of NCT numbers to identify each study.
Delivering new, potentially effective treatments to glioblastoma patients who are routinely faced with tumor recurrence and limited options can significantly extend life expectancy. The early‑phase platform accelerates drug development, allowing patients to access experimental therapies sooner, which is crucial in a disease where the standard of care offers only modest survival benefits.
Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Related signals
- Phase 2b Trial for Cancer Vaccine in Newly Diagnosed Glioblastoma Will Continue
- Glioma
- Clinical trial links oncolytic immunoactivation to survival in glioblastoma
- Tumour treating fields therapy for glioblastoma: current advances and future directions
- Treating the invisible target: treatment planning targeting the microscopic tumor spread in gliomas